Metabolism of Triacylglycerols

Metabolism of Triacylglycerols

Metabolism of Triacylglycerols

On this page

TAGs Overview & Digestion - TAG Team Intro

  • Structure: Glycerol + 3 FAs (ester bonds); hydrophobic, energy store.
  • Dietary Digestion:
    • Mouth: Lingual lipase (minor).
    • Stomach: Gastric lipase (minor; key in infants).
    • Small Intestine: Pancreatic lipase (major) + Colipase. Hydrolyzes $sn-1, sn-3 \rightarrow$ 2-MAG + FFAs.
  • Bile Salts: Emulsify fats $\rightarrow$ micelles; $\uparrow$ surface area for lipase.
  • Absorption (Enterocytes):
    • 2-MAG & long-chain FFAs absorbed.
    • Short/medium-chain FAs $\rightarrow$ portal blood.
  • Re-synthesis & Transport:
    • In enterocytes: 2-MAG + FFAs $\rightarrow$ TAGs.
    • TAGs + Apo B-48 $\rightarrow$ Chylomicrons.
    • Chylomicrons $\rightarrow$ Lymph (lacteals) $\rightarrow$ Blood.

Apo B-48 is exclusively found in chylomicrons, distinguishing them from VLDL (which contains Apo B-100).

TAG Synthesis (Lipogenesis) - Fat Factory Fun

  • Primary Sites: Liver, adipose tissue, lactating mammary glands, intestinal mucosa.

  • Substrates: Glycerol-3-Phosphate (G3P), Fatty Acyl-CoA.

  • G3P Sources:

    • Liver/Kidney: Glycerol $\xrightarrow{\text{Glycerol Kinase}}$ G3P.
    • Liver/Adipose: DHAP (Glycolysis) $\xrightarrow{\text{Glycerol-3-P Dehydrogenase}}$ G3P.
  • FA Activation: Fatty Acid + CoA + ATP $\xrightarrow{\text{Acyl-CoA Synthetase (Thiokinase)}}$ Fatty Acyl-CoA.

  • Pathway: 📌 "Good Apples Pay Dearly" (GPAT, AGPAT, PAP, DGAT)

    • Enzymes: Glycerol-3-phosphate acyltransferase (GPAT), Acylglycerophosphate acyltransferase (AGPAT), Phosphatidic acid phosphatase (PAP/Lipin), Diacylglycerol acyltransferase (DGAT).
  • Regulation: Insulin ↑ TAG synthesis (induces GPAT, DGAT; ↑ glucose for G3P & FA).

  • Export: Liver TAGs → VLDL (ApoB-100). Triacylglycerol Metabolism Pathway synthesis)

⭐ Phosphatidic acid phosphatase (PAP/Lipin) is a pivotal regulatory enzyme, converting PA to DAG, a committed step.

TAG Mobilization (Lipolysis) - Energy Release Party

  • Site: Adipose tissue (stored TAGs).
  • Process: TAGs $\rightarrow$ FFAs + Glycerol.
  • Key Enzymes:
    • ATGL (Adipose Triglyceride Lipase): TAG $\rightarrow$ DAG + FFA.
    • HSL (Hormone-Sensitive Lipase): DAG $\rightarrow$ MAG + FFA (Rate-limiting; PKA-activated).
    • MGL (Monoacylglycerol Lipase): MAG $\rightarrow$ Glycerol + FFA.
  • Hormonal Regulation:
    • Stimulators (↑cAMP/PKA): Catecholamines (Epinephrine, Norepinephrine), Glucagon, ACTH $\rightarrow$ ↑HSL & Perilipin activity (phosphorylation).
    • Inhibitor (↓cAMP): Insulin $\rightarrow$ ↓HSL activity (promotes dephosphorylation via phosphodiesterase & phosphatase activation).
  • Fate:
    • Glycerol: To liver (requires Glycerol Kinase) $\rightarrow$ Glycerol-3-Phosphate ($G3P$) $\rightarrow$ Glycolysis / Gluconeogenesis. (Adipocytes lack glycerol kinase).
    • FFAs: Blood (albumin-bound) $\rightarrow$ Tissues (e.g., muscle for $\beta$-oxidation $\rightarrow ATP$) or Liver (ketogenesis during prolonged fasting).

⭐ HSL is the main hormonally regulated enzyme in lipolysis. Activated by phosphorylation (via PKA from Glucagon/Epinephrine); inactivated by dephosphorylation (via phosphatase, promoted by Insulin).

Hormonal regulation of lipolysis

TAG Clinical Correlations - Lipid Trouble Spots

  • Hypertriglyceridemia: ↑ Fasting TAGs.
    • Levels (mg/dL): Normal <150; Borderline 150-199; High 200-499; Very High ≥500.
    • Causes:
      • Primary: Genetic (e.g., LPL/ApoC-II deficiency).
      • Secondary: Obesity, Type 2 Diabetes, metabolic syndrome, alcohol, hypothyroidism, drugs.
    • Significance: Risk for pancreatitis (esp. TAGs >1000 mg/dL), cardiovascular disease.
  • LPL/Apo C-II Deficiency (Type I Hyperlipoproteinemia):
    • Massive fasting chylomicronemia.
    • Features: Eruptive xanthomas, hepatosplenomegaly, recurrent pancreatitis.
    • No increased atherosclerosis risk.

    ⭐ In LPL or ApoC-II deficiency (Type I Hyperlipoproteinemia), despite massive chylomicronemia and pancreatitis risk, atherosclerosis risk is NOT typically increased.

  • Fatty Liver Disease (Steatosis): TAG accumulation in hepatocytes.
    • Non-alcoholic fatty liver disease (NAFLD): Assoc. with insulin resistance, obesity.
    • Alcoholic fatty liver disease (AFLD): Due to alcohol.

High‑Yield Points - ⚡ Biggest Takeaways

  • HSL (activated: glucagon/epinephrine; inhibited: insulin) mobilizes stored TAGs.
  • LPL (activated: Apo C-II) clears TAGs from chylomicrons/VLDL for tissue uptake.
  • Glycerol from TAGs fuels hepatic gluconeogenesis or glycolysis.
  • Mitochondrial β-oxidation of fatty acids yields Acetyl-CoA, NADH, FADH2.
  • Carnitine shuttle (CPT-I is rate-limiting, inhibited by Malonyl-CoA) transports LCFAs into mitochondria.
  • TAGs are synthesized from glycerol-3-P & fatty acyl-CoAs in liver/adipose tissue.
  • Insulin promotes TAG storage and inhibits lipolysis.

Practice Questions: Metabolism of Triacylglycerols

Test your understanding with these related questions

A person switches from a high-fat diet to a low-fat diet with a compensatory increase in carbohydrates to maintain the same caloric intake. Which lipoprotein is likely to increase?

1 of 5

Flashcards: Metabolism of Triacylglycerols

1/10

Triglycerides in chylomicrons are hydrolyzed by the enzyme _____, releasing free fatty acids

TAP TO REVEAL ANSWER

Triglycerides in chylomicrons are hydrolyzed by the enzyme _____, releasing free fatty acids

lipoprotein lipase (LPL)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial